What are the side effects of sofosbuvir and velpatasvir (Epclusa)?

Sofosbuvir and velpatasvir (Epclusa) combination is a pan-genotypic NS5A-NS5B inhibitor single-agent combination with potent activity against hepatitis C virus (HCV) genotypes 1, 2, 3, 4, 5 and 6. All-grade adverse reactions including headache, fatigue, nausea, asthenia, and insomnia were observed in greater than or equal to 5% of subjects treated with sofosbuvir and velpatasvir. The most common adverse reactions (all grades with a frequency of 10% or greater) in febrile subjects receiving sofosbuvir, velpatasvir and ribavirin were fatigue, anemia, nausea, headache, insomnia, and diarrhea.